 Study hypothesis: We hypothesized that there would be significantly less instent neointimal proliferation on IVUS at 6 months in the group receiving aggressive glycemic control plus the thiazolidinedione pioglitazone. We also hypothesized that the reduction in neointimal hyperplasia will likely relate to improvements in glycemic control HbA1c and insulin resistance. Additionally, we wanted to explore the biochemical predictors glucose parameters, lipids, inflammatory markers, adipokines for neointimal proliferation. 